temozolomide and bevacizumab

DRUG2 trials

Sponsors

Kentuckiana Cancer Institute, Center for Neurosciences, Tucson

Conditions

GliomaRecurrent Glioblastoma MultiformeRecurrent Gliosarcoma

Phase 2

A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma

Kentuckiana Cancer InstituteGlioma

Start: 2008-04-30End: 2010-12-31Target: 40Updated: 2010-01-20

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

CompletedNCT00883298

Center for Neurosciences, TucsonRecurrent Glioblastoma Multiforme, Recurrent Gliosarcoma

Start: 2009-04-30End: 2014-12-01Updated: 2017-03-30